EDGEWISE THERAPEUTICS INC (EWTX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for EWTX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| EWTX | Director | 69 | ["BridgeBio Pharma, Inc., President and Chief Medical Officer","President and Chief Medical Officer at BridgeBio Pharma, Inc.","Chief Medical Officer of MyoKardia, Inc.","Senior advisor at MyoKardia, Inc.","Consultant at Nigel-Montgomery, LLC","Various senior positions at SmithKline Beecham, Merck Research Laboratories, AstraZeneca","Adjunct faculty at Stanford University Cardiovascular Institute","Board member at ML BioSolutions","Trustee of the Lankenau Institute for Medical Research","A.B. in biology from the University of Chicago","Ph.D. in experimental pathology from the University of Chicago","M.D. from the University of Chicago","Training in Internal Medicine and Cardiology at Duke University","ABIM Certified in Cardiovascular Diseases","Fellow of the American College of Cardiology"] | ["Nominating & Corporate Governance"] | 2026 |
Biography sourced from the proxy statement filing.
Jonathan Fox, M.D., Ph.D. joined our board of directors in March 2023. Dr. Fox has served as the president and Chief Medical Officer for the cardiovascular and renal diseases division at BridgeBio Pharma, Inc., a clinical stage biotechnology company developing novel, genetically targeted therapies since 2016. Prior to that, Dr. Fox served as the Chief Medical Officer of MyoKardia, Inc., a clinical-stage biopharmaceutical company focused on targeted therapies for serious cardiovascular diseases, from 2013 to 2016 and as a senior advisor from 2016 to 2017. Additionally, he worked as a consultant at Nigel-Montgomery, LLC, a technology research and advisory company, from 2012 to 2013 and held various senior positions successively at SmithKline Beecham, a pharmaceutical manufacturing company, Merck Research Laboratories, the research and development division of Merck & Co., Inc., and AstraZeneca, a biopharmaceutical company focused on oncology, rare diseases, and various biopharmaceutical applications, from 1998 to 2012. He was also on the faculty of the University of Pennsylvania School of Medicine from 1993 to 2013. Since 2013, he has held an adjunct faculty position at the Stanford University Cardiovascular Institute. Dr. Fox serves on the board at ML BioSolutions, a private company focused on developing an oral treatment for limb girdle muscular dystrophy, and is a trustee of the Lankenau Institute for Medical Research, a nonprofit organization. He received his A.B. in biology, his Ph.D. in experimental pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases and is a Fellow of the American College of Cardiology. We believe Dr. Fox s strong technical background, experience in cardiovascular clinical development and product approvals and extensive experience in management in the biotechnology industry provides him with the qualifications and skills to serve as a member of our board of directors.